<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303055</url>
  </required_header>
  <id_info>
    <org_study_id>AGU-248</org_study_id>
    <nct_id>NCT01303055</nct_id>
  </id_info>
  <brief_title>Effects of Alogliptin on Pancreatic Beta Cell Function</brief_title>
  <official_title>Multicenter Trial on Effects of Alogliptin on Pancreatic Beta Cell Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aichi Gakuin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aichi Gakuin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is reported that pancreatic beta cell function is already declined at pre-diabetic stage,
      impaired glucose tolerance (IGT). It has not been clarified whether inhibitors of the
      dipeptidyl peptidase IV enzyme (DPP-IV inhibitors) improve beta cell function on human
      pancreas, however, if efficacy is ensured, they may become the first medicine to be chosen
      for treatments of type 2 diabetes and IGT.

      In this trial, a DPP-IV inhibitor, Alogliptin, or Metformin are given to diabetic patients
      whose HbA1c level is below 7.9%. Oral glucose tolerance test (OGTT) will be conducted before,
      a year after, and two years after the beginning of the trial and beta cell function will be
      evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly allocated to two groups. They will receive either Alogliptin or
      Metformin.

      Alogliptin: The investigators will start with 25 mg QD and the dose will be maintained.

      Metformin: The investigators will start with 250 mg QD and the dose will be slowly increased
      to 750 mg TID. The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is
      maintained below 6.9%. However, increase in dose with elder patients requires careful
      consideration.

      Participants taking part in this study will receive dietary and exercise coaching.
      Participation in this study is expected to last up to 2 years.

      Patients will terminate from the trial when their HbA1c exceeds 8.4% for more than three
      months.

      The investigators will evaluate beta cell function by conducting 75 g OGTT before, a year
      after, and two years after the beginning of the trial. Alogliptin or Metformin will be
      stopped three days before the OGTT. The investigators will make sure that urine ketone is
      negative before an oral glucose load.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>beta cell function evaluated from 75 g OGTT</measure>
    <time_frame>2 years</time_frame>
    <description>75 g OGTT: glucose level, blood insulin level, c-peptide immunoreactivity (pre-test, 30 mins, 60 mins, 120 mins), fasting blood proinsulin
Oral glucose tolerance test ( OGTT ) will be conducted before, a year after, and two years after the beginning of the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1,5-AG level</measure>
    <time_frame>2 years</time_frame>
    <description>Secondary end points include HbA1c level.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Alogliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 750 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin 25 mg, tablets, orally, once daily : two years</description>
    <arm_group_label>Alogliptin</arm_group_label>
    <other_name>Nothing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 750 mg</intervention_name>
    <description>Metformin 750 mg, tablets, orally, thrice daily: two years
The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Nothing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are diagnosed as type 2 diabetes with HbA1c level below 7.9% and haven't
             received oral hypoglycemic agents or insulin treatments for the past three months.

        Exclusion Criteria:

          -  Patients whose 75 g OGTT 30-minutes insulin secretion exceeds 100 μU/ml

          -  Patients with renal failure with serum creatinine level ≧ 1.2

          -  Patients with hepatocirrhosis

          -  Patients with proliferative diabetic retinopathy or worse

          -  Patients with acute infectious disease

          -  Patients who are treated with steroids

          -  Patients with cancer

          -  Pregnant patients

          -  Patients with malfunction of the heart (NYHA classification III-IV)

          -  Patients who are decided to be inappropriate subjects by study physicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takahiro Tosaki, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aichi Gakuin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takahiro Tosaki, MD, PhD</last_name>
    <phone>+81-52-759-2111</phone>
    <email>nrd49075@nifty.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <phone>+81-52-759-2111</phone>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keiko Naruse, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tosaki Clinic for Diabetes and Endocrinology</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>468-0009</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes Clinic, Okazaki East Hospital</name>
      <address>
        <city>Okazaki</city>
        <state>Aichi</state>
        <zip>444-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <phone>+81-564-22-6616</phone>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Chizuko Suzuki, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maiko Mizutani, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes Center, Yokkaichi Social Insurance Hospital</name>
      <address>
        <city>Yokkaichi</city>
        <state>Mie</state>
        <zip>510-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <phone>+81-59-331-2000</phone>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Miho Miyoshi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomoki Majima, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Takahiro Tosaki</name_title>
    <organization>Aichi Gakuin University</organization>
  </responsible_party>
  <keyword>Pancreatic beta Cell</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Metformin</keyword>
  <keyword>Hypoglycemic Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>hemoglobin A1c protein, human</keyword>
  <keyword>Oral Glucose Tolerance Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alogliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

